^
    14d
    A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF) (clinicaltrials.gov)
    P1/2, N=21, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=93 --> 21 | Trial completion date: May 2027 --> Dec 2025 | Recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Dec 2025; Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    TQB3909 • rovadicitinib (TQ05105)
    21d
    TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) (clinicaltrials.gov)
    P1/2, N=19, Terminated, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | N=39 --> 19 | Recruiting --> Terminated; Study terminated for strategic business reasons
    Enrollment change • Trial termination
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    TQB3909
    8ms
    A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies (clinicaltrials.gov)
    P1/2, N=138, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P1/2 trial
    |
    azacitidine • TQB3909
    over1year
    A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF) (clinicaltrials.gov)
    P1/2, N=93, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting | Initiation date: Feb 2024 --> May 2024
    Enrollment open • Trial initiation date
    |
    TQB3909 • rovadicitinib (TQ05105)
    almost2years
    A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF) (clinicaltrials.gov)
    P1/2, N=93, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P1/2 trial
    |
    TQB3909 • rovadicitinib (TQ05105)
    2years
    A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy (clinicaltrials.gov)
    P1, N=208, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P1 trial
    |
    TQB3909
    2years
    A Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P1 trial
    |
    itraconazole • TQB3909 • rifampicin
    2years
    TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) (clinicaltrials.gov)
    P1/2, N=39, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
    New P1/2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    TQB3909
    2years
    A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . (clinicaltrials.gov)
    P1/2, N=107, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PLCG2 (Phospholipase C Gamma 2)
    |
    TQB3909
    over2years
    A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . (clinicaltrials.gov)
    P1/2, N=107, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P1/2 trial
    |
    PLCG2 (Phospholipase C Gamma 2)
    |
    TQB3909
    almost3years
    A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer (clinicaltrials.gov)
    P1/2, N=65, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P1/2 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    TQB3909
    almost4years
    A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors (clinicaltrials.gov)
    P1, N=126, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting | Initiation date: Nov 2021 --> Feb 2022
    Enrollment open • Trial initiation date • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2 expression
    |
    TQB3909